Advances in the early detection and treatment of lung cancer have led to significant improvements in prognosis and survival in recent years. The COVID-19 pandemic has created an unprecedented environment that threatens to diminish that progress.

In Biodesix’s webinar presentation, three lung cancer experts will discuss balancing COVID-19 exposure risk from diagnostic procedures with the pursuit of early diagnosis of lung cancer. Topics to be covered include COVID-19 policies and guidelines that impact detection and diagnosis, improvement of early detection, time to diagnosis and treatment, and how telemedicine and blood-based lung nodule testing can address the need for improved nodule classification and early diagnosis during the COVID-19 pandemic.

Learn more and register.